[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"secondary-prevention\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:secondary-prevention":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,76,108,138,167,194],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100634682","aspirin-50-mg-vs-100-mg-in-elderly-cardiovascular-disease-patients-100634682",false,"NCT07542860","Aspirin 50 mg vs. 100 mg in Elderly Cardiovascular Disease Patients","Risk Assessment and Application of Antithrombotic Therapy in Elderly Patients With Cardiovascular Disease: A Multicenter, Prospective Cohort Study","LAPIS","Inclusion Criteria:\n\n1. Age ≥ 60 years.\n2. Diagnosis of established atherosclerotic cardiovascular disease (ASCVD), including acute coronary syndrome, stable coronary artery disease, post-revascularization (percutaneous coronary intervention or coronary artery bypass grafting), ischemic cardiomyopathy, ischemic stroke, transient ischemic attack, or peripheral artery disease.\n3. Long-term use of aspirin (≥1 year) for secondary prevention of ASCVD.\n4. Available laboratory tests (within the past 3 months): complete blood count, urinalysis, routine stool examination and occult blood test, liver and kidney function, electrolytes, glucose, lipids, uric acid, coagulation function, etc.\n5. Willing to provide written informed consent.\n\nExclusion Criteria:\n\n1. Hypersensitivity to aspirin or other salicylates, or any other component of the drug product; history of asthma induced by salicylates or nonsteroidal anti-inflammatory drugs (NSAIDs), or any other condition that, in the clinical judgment, makes the patient unsuitable for study participation.\n2. Life expectancy ≤ 2 years due to non-cardiovascular causes.\n3. Poor compliance (unable to adhere to prescribed medication or follow scheduled follow-up visits as judged by the investigator).","ALL","60 Years",{"count":20,"type":21},5448,"ESTIMATED","3 Years","OBSERVATIONAL","Elderly patients with cardiovascular disease face a high risk of both thrombotic and bleeding events when receiving antithrombotic therapy. The optimal dose of aspirin for secondary prevention in this population remains uncertain, particularly in Chinese elderly individuals. This multicenter, prospective cohort study aims to evaluate the effectiveness and safety of a lower dose of aspirin (50 mg daily) compared with the standard dose (100 mg daily) for secondary prevention of atherosclerotic cardiovascular disease (ASCVD) in Chinese patients aged 60 years and older. The study is an extension of the existing LAPIS cohort (ChiCTR1900021980), which has enrolled 5,448 participants receiving long-term aspirin for secondary prevention. Participants will be followed for an additional 2 years (total follow-up up to approximately 6 years) through telephone, clinic visits, and electronic medical records. The primary effectiveness outcome is the first occurrence of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, unstable angina, need for revascularization, non-fatal stroke, transient ischemic attack, and cardiovascular death (excluding intracranial bleeding). The primary safety outcome is the first occurrence of bleeding events (classified by BARC criteria). A secondary aim is to develop and validate a risk prediction model (nomogram) for thrombotic and bleeding events specifically for elderly Chinese patients receiving antithrombotic therapy, using LASSO regression and Cox proportional hazards models. The study will provide real-world evidence to guide individualized antithrombotic management in the aging Chinese population.",[26,27,28],"Atherosclerotic Cardiovascular Disease (ASCVD)","Secondary Prevention","Cardiovascular Diseases",[30,27,28,31,32],"Aspirin","Aged","Risk Assessment","RECRUITING","2026-04-14",{"date":36,"type":37},"2026-04-21","ACTUAL",{"date":39,"type":37},"2019-04-10",{"date":41,"type":21},"2027-12-31",{"name":43,"class":44},"Peking University First Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100622345","electronic-letters-to-improve-patient-activation-in-ihd-the-nudge-ihd-trial-100622345","NCT07382414","Electronic Letters to Improve Patient Activation in IHD: The NUDGE-IHD Trial","NUDGE-IHD: A Nationwide Pragmatic Randomized Trial of Electronic Nudges to Increase Patient Activation to Support Risk-factor Control in Ischemic Heart Disease","NUDGE-IHD","Inclusion criteria\n\n* Alive on identification date\n* Diagnosis of IHD defined as either an A or B diagnosis code of I20-I25 in the Danish National Patient Register first registered \\> 6 months prior to identification date\n* Latest available LDL-C is over 1.4 mmol\u002Fl measured up to 3 years prior to the identification date, defined using NPU codes NPU01568, NPU10171 or DNK35308 from the Danish National Laboratory Register\n* Age \\>= 18 years and \\\u003C= 85 on identification date\n\nExclusion criteria\n\n* Nursing home residents\n* Exemption from and thus not access to Digital Post","18 Years","85 Years",{"count":57,"type":21},100000,"INTERVENTIONAL",[60],"NA","The goal of this clinical trial is to learn whether simple electronic information letters can increase patient activation and improve risk-factor monitoring in adults in Denmark with ischemic heart disease (IHD) who have LDL cholesterol above the recommended treatment target. A subgroup of participants with elevated lipoprotein(a) \\[Lp(a)\\] will also be randomized to receive an additional information letter.\n\nThe main questions the study aims to answer are:\n\n* Does sending an electronic letter about elevated LDL cholesterol increase the proportion of patients who have at least one LDL-cholesterol test within 6 months?\n* Among patients with ischemic heart disease and elevated Lp(a), does receiving an information letter about Lp(a) increase patient activation, reflected by cardiometabolic risk-factor monitoring?\n\nBecause this is a randomized trial, researchers will compare people who receive the electronic letter(s) with people who do not receive any letter to determine whether the letters encourage patients to take action, such as obtaining laboratory tests or contacting their doctor.\n\nParticipants will:\n\n* Receive an electronic letter through Denmark's national digital mailbox system (Digital Post) or receive no letter, depending on random assignment.\n* Continue their usual health care, with no additional visits, treatments, or procedures required for the study.\n* Have all study information collected from existing Danish nationwide health registries.",[63,64,65,27],"Coronary Artery Disease","Hypercholesterolemia","Lipoprotein(a)","NOT_YET_RECRUITING","2026-03-08",{"date":69,"type":37},"2026-03-10",{"date":71,"type":21},"2026-04",{"date":73,"type":21},"2026-10",{"name":75,"class":44},"Tor Biering-Sørensen",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":58,"phases":86,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100626803","phase-3-triple-oral-therapy-with-bempedoic-acid-vs-usual-care-in-early-lipid-management-of-patients-with-acute-coronary-syndrome-100626803","NCT07440381","triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE","triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE (PERSUADE) Trial","PERSUADE","Inclusion Criteria:\n\n* Age ≥18 years\n* Male and females at birth\n* Admitted for ACS caused by an atherothrombotic coronary event;\n* Calculated LDL-c: 70-140 mg\u002FdL within 24 hours from admission for the ACS index event\n* Lipid lowering therapy on admission consisting of a low\u002Fmoderate intensity statin or a high intensity statin (HIS); or no lipid lowering therapy (naïve patients)\n* Lipid-lowering therapy at discharge (at the time of randomization) consisting of HIS or HIS + ezetimibe\n* Scheduled home discharge\n* Written informed consent provided; patients who are unable to give informed consent for any reason will be excluded from the study.\n\nExclusion Criteria:\n\n* Patients already treated with HIS+Ezetimibe on admission for the ACS event,\n* Patients currently, previously or planned to be treated with PCSK9i or inclisiran,\n* Patients treated currently or in the last 3 months with bempedoic acid or in whom this treatment is planned in the following 8 weeks,\n* Known allergy, sensitivity or intolerance to bempedoic acid and\u002For study drugs' formulation ingredients (e.g. lactose intolerance),\n* Patients with history of documented intolerance to statins, ezetimibe or bempedoic acid\n* Patients with known Familial Hypercholesterolemia (FH; heterozygous or homozygous),\n* Patients with plasma triglycerides concentration exceeding 400 mg\u002FdL (4.52 mmol\u002FL),\n* Patients with dysbetalipoproteinemia (type III hyperlipoproteinemia),\n* Unstable clinical status (hemodynamic or electrical instability),\n* Severe renal dysfunction (eGFR \\\u003C30 ml\u002Fmin\u002F1.73m2 using the CKD-EPI formula),\n* Active liver disease or hepatic dysfunction (AST or ALT levels \\> 3xUNL),\n* Current enrolment in another investigational device or drug study,\n* Current pregnancy, lactation or women of childbearing potential, unless using highly effective contraception,\n* Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.",{"count":85,"type":21},600,[87],"PHASE3","Early and intensive LDL-cholesterol (LDL-c) reduction is associated with improved short-term and long-term outcomes. Bempedoic acid is an oral ATP citrate lyase inhibitor that lowers LDL-c upstream of HMG-CoA reductase. When added to maximally tolerated statins, it has demonstrated significant LDL-c reduction and cardiovascular benefit, particularly in statin-intolerant or high-risk patients. However, evidence on early initiation of bempedoic acid during the index ACS hospitalization is currently lacking. The investigators therefore would like to see whether early (pre-discharge) initiation of an oral triple lipid-lowering therapy including bempedoic acid, high-intensity statin (HIS), and ezetimibe is superior to usual care in reducing LDL-c levels at 8 weeks after randomization in patients hospitalized for ACS.",[90,27,91],"Acute Coronary Syndromes","Lipids",[93,94,95,96,97],"ACS","Lipid-lowering therapy","atherothrombotic coronary event","secondary prevention","triple oral lipid lowering therapy","2026-02-26",{"date":100,"type":37},"2026-02-27",{"date":102,"type":21},"2026-09",{"date":104,"type":21},"2027-08",{"name":106,"class":44},"Heart Care Foundation",35,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":58,"phases":117,"briefSummary":118,"conditions":119,"keywords":124,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":45},"100624296","the-southern-norway-post-stroke-atrial-fibrillation-study-100624296","NCT07407790","The Southern-Norway Post-Stroke Atrial Fibrillation Study","SNAPS","Inclusion Criteria:\n\n* Patients hospitalized with an ischemic stroke or transient ischemic attack (TIA), including amaurosis fugax, occurring within the last 2 weeks.\n* Initial evaluation of CT and\u002For CT angiography and\u002For MRI supports a diagnosis of TIA or ischemic stroke.\n* Available smartphone and access to the ECG247-app to be able to participate in the study.\n* Estimated life span of \\>6 month\n* Permanent address in Norway\n* Informed Consent, Capable of giving signed informed consent or consent through proxy as described in Appendix which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the study protocol.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\nMedical Conditions\n\n* Known AF or atrial flutter prior to inclusion\n* Concomitant use of anticoagulation therapy or established contraindication to its use. To date this includes apixaban, rivaroxaban, edoxaban, dabigatran, warfarin and indirect thrombin inhibitors (except for short term thrombosis prevention).\n* Implanted pacemaker, ICD or loop-recorder\n* \\>70% stenosis of carotid artery on ipsilateral side to the stroke on CT angiography or ultrasound\n* Pregnancy",{"count":116,"type":21},450,[60],"This study evaluates whether a procedure using a new wireless heart sensor patch is equal to or better than the standard hospital procedures and equipment at detecting an irregular heartbeat called Atrial Fibrillation (AF) after an ischemic stroke. Atrial fibrillation is a major cause of stroke, but it can be difficult to catch because it often comes and goes.\n\nThe study will include approximately 450 adults who have had a stroke or a transient \"mini-stroke\" (TIA) within the last two weeks. Participants will be assigned by chance (randomized) to one of two groups:\n\n* Group 1 (Intervention): Participants wear the \"ECG247 Smart Heart Sensor.\" This is a small patch that sticks to the chest and connects to a smartphone. It is worn continuously for up to 14 days, even after leaving the hospital.\n* Group 2 (Standard Care): Participants receive the standard hospital check-up. This typically involves using a \"Holter monitor\" (a device with wires and electrodes) for a period of about 24 to 48 hours some time after leaving the hospital.\n\nThe main goal is to see if the procedure using the patch is equal to the standard procedure in detecting atrial fibrillation in participants. The study will also measure how quickly doctors can start the correct medication and how easy the patients find the devices to use.",[120,121,122,27,123],"Atrial Fibrillation (AF)","Atrial Fibrillation (Prevention of Stroke)","Ischemic Stroke","Arrhythmia Atrial",[125,126,127],"stroke","atrial fibrillation","anticoagulation","2026-02-05",{"date":130,"type":37},"2026-02-12",{"date":132,"type":37},"2026-01-10",{"date":134,"type":21},"2029-12",{"name":136,"class":137},"Sorlandet Hospital HF","OTHER_GOV",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":146,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":58,"phases":149,"briefSummary":150,"conditions":151,"keywords":154,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":166},"100565981","optimal-target-low-density-lipoprotein-cholesterol-level-for-small-vessel-occlusion-stroke-100565981","NCT06649240","Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke","Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke (SVO70)","SVO70","Inclusion Criteria:\n\n1. Age 19 years or older\n2. Patients with objectively confirmed small vessel occlusive infarctions in the subcortical or brainstem regions, identified through neuroimaging (MRI or CT)\n3. Patients with a history of symptomatic ischemic stroke caused by the lesion described in 2), occurring within 180 days prior to enrollment\n4. Patients or guardians who agree to the study protocol and sign with informed consent\n\nExclusion Criteria:\n\n1. Patients requiring intensive LDL cholesterol management (LDL-C \\\u003C70 mg\u002FdL) due to another condition, with LDL cholesterol targets specified in the guidelines for that condition\n2. Patients contraindicated for statin use (e.g., active liver disease, serum transaminase levels elevated more than three times the normal limit, muscle disorders, hypersensitivity to statins, or taking medications contraindicated for use with statins)\n3. Women who are pregnant, breastfeeding, or intending to become pregnant during the study period\n4. Deemed unsuitable for participation in the study for more than four years, as per the investigators' discretion","19 Years",{"count":148,"type":21},4016,[60],"Lipid-lowering therapy constitutes a cornerstone of secondary prevention in ischemic stroke; however, current stroke guidelines remain deficient in providing optimal target low-density lipoprotein (LDL)-cholesterol levels tailored to the stroke subtypes. Most clinical trials on LDL-cholesterol management have not differentiated between stroke subtypes or have primarily focused on large artery atherosclerosis (LAA) stroke, leaving a gap in evidence for managing LDL-cholesterol in other stroke subtypes, e.g., small vessel occlusion (SVO) stroke. While hypertension is the leading risk factor for SVO strokes, the link between elevated LDL-cholesterol and SVO stroke is also recognized. Establishing optimal LDL-cholesterol targets for SVO stroke would significantly enhance secondary prevention strategies and improve patient outcome. Thus, the investigators aim to compare intensive versus standard lipid-lowering in patients with SVO stroke. SVO70 is a multicenter, prospective, randomized, open, blinded-endpoint clinical trial. Adult participants with objectively confirmed SVO stroke within 180 days of randomization will be included. Exclusion criteria include those with predefined LDL-cholesterol targets for other conditions, statin contraindications, or women who are pregnant, breastfeeding, or planning pregnancy during the study period. Eligible participants will be randomized 1:1 to target LDL-cholesterol \\\u003C70 mg\u002FdL (intensive group) or 90-110 mg\u002FdL (standard group). The trial plans to enroll 4,016 participants, with the primary outcome being major adverse cardiovascular events-cardiovascular death, stroke, and acute coronary syndrome-during a follow-up period of at least 4 years. This study would provide valuable information for determining the optimal LDL-cholesterol target for patients with SVO stroke.",[122,152,153,27,28],"Small Vessel Cerebrovascular Disease","Cholesterol, LDL",[155,122,27,153,156],"Cerebral Small Vessel Diseases","Statins","2025-05-17",{"date":159,"type":37},"2025-05-21",{"date":161,"type":37},"2024-10-04",{"date":163,"type":21},"2030-09",{"name":165,"class":44},"Seoul National University Hospital",46,{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":58,"phases":177,"briefSummary":178,"conditions":179,"keywords":182,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":45},"100555350","improving-therapeutic-adherence-in-cardiovascular-secondary-prevention-100555350","NCT06510946","Improving Therapeutic Adherence in Cardiovascular Secondary Prevention.","Efficacy of an Intervention to Increase Therapeutic Adherence in Patients With Secondary Prevention for Cardiovascular Disease.","AT-PSC","Inclusion Criteria:\n\n* Patients of both sexes, aged over 18 years old, who, after reading the patient information sheet, provide written informed consent.\n* Patients in secondary prevention receiving daily single-dose angiotensin converting enzyme inhibitors\u002FAngiotensin II receptor blockers, acetylsalicylic acid, and statins for 6 months or more.\n* Diagnosis of any of the following cardiovascular diseases: cerebrovascular disease, ischemic heart disease, or peripheral vascular disease.\n* Patients under follow-up at our primary care center.\n* Patients identified with therapeutic adherence deficiency, defined as Haynes-Sackett test supplemented with Medication Possession Ratio (MPR) \\\u003C 80% for any of the 3 drugs in the previous 6 months.\n\nExclusion Criteria:\n\n* Patients who refuse to participate.\n* Incomplete completion of informed consent.\n* Language barrier.\n* Patients diagnosed with psychiatric, psychological, neurological, and\u002For social problems that hinder intervention or follow-up.\n* Life expectancy less than one year.\n* Patients whose treatment is managed by a caregiver (professional or family member).\n* Patients with Barthel Index \\\u003C60.\n* Institutionalized patients.\n* Patients currently participating in similar research studies.",{"count":176,"type":21},90,[60],"The goal of this open label randomized controlled trial is to evaluate the efficacy of an intervention through health education based on the Chronic Care Model's implementation to increase therapeutic adherence in patients with secondary prevention for cardiovascular disease. The main questions it aims to answer are:\n\n* Null hypothesis (H0): In patients in cardiovascular secondary prevention, an intervention based on the application of the Chronic Care Model does not improve therapeutic adherence to the 3 preventive drugs: Angiotensin converting enzyme inhibitors\u002FAngiotensin II receptor blockers, acetylsalicylic acid, and statins.\n* Alternative hypothesis (H1): In patients in cardiovascular secondary prevention, an intervention based on the application of the Chronic Care Model improves therapeutic adherence to the 3 preventive drugs: Angiotensin converting enzyme inhibitors\u002FAngiotensin II receptor blockers, acetylsalicylic acid, and statins.\n\nResearchers will compare intervention group (health education, use of mobile phones, personalized dosage system) to the control group (routine follow-up).",[28,180,27,181],"Chronic Disease","Coronary Disease",[183,184],"Treatment Adherence and Compliance","Primary Health Care","2024-07-18",{"date":187,"type":37},"2024-07-19",{"date":189,"type":21},"2025-01",{"date":191,"type":21},"2026-01",{"name":193,"class":44},"Universidad Miguel Hernandez de Elche",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":199,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":201,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":58,"phases":205,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":45},"100534769","phase-4-pair-antiplatelet-therapy-in-ischemic-stroke-with-intracranial-artery-stenosis-100534769","NCT06243133","Pair Antiplatelet THerapy in Ischemic Stroke With Intracranial Artery Stenosis","PATH-ICAS","Inclusion Criteria:\n\n1. Age 40 \\~ 80 years old;\n2. Patients diagnosed as non-cardiogenic cerebral infarction according to the WHO definition of stroke, with MRA\u002FCTA\u002FDSA confirmed intracranial artery stenosis ≥50% (intracranial carotid artery, M1 and proximal M2 segment of middle cerebral artery, A1 and A2 segment of anterior cerebral artery, P1 and P2 segment of posterior cerebral artery, intracranial vertebral artery and basilar artery);\n3. First stroke onset within 7 days;\n4. NIHSS score ≤5;\n5. Patients or family members sign informed consent forms;\n\nExclusion Criteria:\n\n1. Patients receiving thrombolysis or endovascular therapy;\n2. Patients with recurrent stroke;\n3. Patients has undergone major surgery or major trauma within the past 30 days;\n4. History of gastrointestinal bleeding, active peptic ulcer, intracranial hemorrhage or other hemorrhagic diseases;\n5. Contraindications or intolerances to the use of antiplatelet therapeutics;\n6. Platelet count \\\u003C100\\*109\u002FL, hemoglobin\\\u003C110g\u002FL;\n7. Patients with severe organ insufficiency or other serious disease (e.g., severe cardiopulmonary failure, advanced tumor, severe dementia);\n8. Patients intolerant to MRI scan are replaced by CT or DSA;\n9. poor compliance, unable to meet the requirements of the study.","40 Years","80 Years",{"count":204,"type":21},1100,[206],"PHASE4","The goal of this clinical trial is to learn about efficacy and safety of dual antiplatelet therapy in ischemic stroke with intracranial artery stenosis. The main question it aims to answer are:\n\nwhether aspirin combined with clopidogrel for 3 month is better than 1 months for patients with non-cardiogenic cerebral infarction with intracranial artery stenosis.\n\nParticipants will get dual antiplatelet therapy (aspirin plus clopidogrel) for 1 month or 3 months within 7 days of the first stroke.\n\nResearchers will compare experimental group (3 months dual antiplatelet therapy) with comparison group (1 month dual antiplatelet therapy), to see if experimental group would reduce stroke recurrence or mortality, and increase bleeding and other adverse prognosis.",[122,209,27,210],"Intracranial Arteriosclerosis","Antiplatelet Drug","2024-06-17",{"date":213,"type":37},"2024-06-18",{"date":215,"type":21},"2024-07-01",{"date":217,"type":21},"2026-03-31",{"name":219,"class":44},"Sichuan Provincial People's Hospital"]